|
|
|
|
|
Click Here to return To Results
|
|
|
|
In long-term octreotide treatment of GH-secreting pituitary adenomas,tumor shrinkage occurs primarily during the first year,but effects are noted up to 4 years.The treatment may be considered an alternative to surgery in the select group of patients in whom the peripheral effects of chronic GH elevation,as determined by serum insulin like growth factor I(IGF-1),are controlled.We suggest MR imaging with T1-weighted coronal and sagittal images at baseline and after 3 and 12 months,with additional MR imaging if GH or IGF-I levels rise during treatment.At baseline,both noncontrast and contrast-enhanced images should be obtained.Unenhanced images may be sufficient during follow-up unless tumor reexpansion or surgery is anticipated. |
|
(click to filter results - removes previous filter)
acromegaly
growth hormone
MRI
MRI,abnormal
MRI,serial
neoplasm,pituitary
neoplasm,pituitary,treatment of
nerve growth factor
octreotide
pituitary,adenoma
prognosis
somatostatin analogue
treatment of neurologic disorder
|
Click Here to return To Results
|
|